Analyst Price Target is $7.97
▲ +30.47% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Autolus Therapeutics in the last 3 months. The average price target is $7.97, with a high forecast of $12.00 and a low forecast of $4.80. The average price target represents a 30.47% upside from the last price of $6.11.
Current Consensus is
The current consensus among 8 investment analysts is to moderate buy stock in Autolus Therapeutics. This Moderate Buy consensus rating has held steady for over two years.
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.